Grade: Pharmaceutical Grade

Factory Location: Xiamen, Fujian

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East

Monthly Production Capacity: 1000kg

Packaging Information: 25kg/drum 1kg/bottle

Delivery Lead Time: 7 days after payment

Sample Provided: yes

Payment Terms: L/L

 

Product Information

 

 

Product name	Dasatinib
Molecular Formula	C22H28CIN7O3S
Molecular Weight	506.02
CAS No.	302962-49-8
Quality Standard	USP26, EP, medical grade
Appearance	White powder

 

 

COA of Dasatinib

 

ITEMS	SPECIFICATION	RESULTS
IDENTIFICATION	POSITIVE REACTION	CONFORMS
Water	≤1.5%	0.9%
LOSS ON DRYING	≤0.1%	0.03%
RESIDUE ON IGNITION	≤0.1%	0.02%
CHROMATOGRAPHIC PURITY	RANITIDINE RELATED COMPOUND B≤0.5% ANY OTHER IMPURITY≤0.3% THE SUM OF ALL IMPURITIES≤1.0%	CONFORMS CONFORMS CONFORMS
ORGANIC VOLATILE IMPURITIES	AS STIPULATED	CONFORMS
ASSAY (ON DRY SUBSTANCE)	98.0%~102.0%	99.8%
CONCLUSION	CONFORMS TO in house

 

Usage

 

Function of Dasatinib

 

Dasatinib (DASA tin IB), used for all treatment stages (chronic phase, accelerated phase) Stage, lymphoid cell blast crisis and myeloid blast crisis) adult patients. At the same time, the FDA also approved Dasatinib through normal procedures to treat Philadelphia chromosome-positive acute lymphoblastic leukemia adult patients who are resistant or intolerant to other therapies.

Dasatinib inhibits BCR-ABL kinase and SRC family kinases as well as many other selective oncogenic kinases, including c-KIT, ephrin (EPH) receptor kinase and PDGFβ receptor. Dasatinib is a potent, subnanomolar BCR-ABL kinase inhibitor with a strong activity at a concentration of 0.6 to 0.8 nmol. It can be combined with the inactive and active configurations of the BCR-ABL enzyme.

In vitro studies, dasatinib is active in leukemia cell lines expressing various imatinib-sensitive and drug-resistant diseases. The results of these non-clinical studies indicate that dasatinib can overcome imatinib resistance caused by: BCR-ABL overexpression, BCR-ABL kinase region mutations, kinases including SRC family kinases (LYN, HCK) in Over-expression of other signaling pathways within, as well as multidrug resistance genes. In addition, dasatinib can inhibit SRC family kinases at this nanomolar concentration

In an in vivo experiment conducted using the murine CML model alone, dasatinib prevented the progression of chronic phase CML to the acute phase, while prolonging tumor-bearing mice (derived from patient CML cell lines growing in different locations, including the central Nervous system)